Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rho kinase: a target for treating urinary bladder dysfunction?

Stephan L M Peters1, Martina Schmidt, Martin C Michel

  • 1Department of Pharmacology and Pharmacotherapy, Academic Medical Center, University of Amsterdam, Amsterdam 1105AZ, The Netherlands.

Trends in Pharmacological Sciences
|July 28, 2006
PubMed
Summary

Rho kinase (ROCK) inhibitors show promise for treating urinary incontinence and bladder dysfunction. These drugs target smooth muscle contraction, offering potential new therapies for common bladder storage symptoms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Botulinum Toxin Type A Injections in the Bladder Wall-An Effective Treatment for Urinary Incontinence with Low Long-Term Adherence.

Toxins·2026
Same author

Letter regarding Pini, A., Nardini, P., Zizi, V., Molino, M., Calvani, M., Carrozzo, F., … Filippi, L. (2026). β3-adrenoceptor agonism exerts lung protection in a rat model of bronchopulmonary dysplasia. Br J Pharmacol, in press.

British journal of pharmacology·2026
Same author

A year in pharmacology: new drugs approved by the US food and drug administration in 2025.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same author

Therapeutic potential of targeting novel signaling pathways in regulating chronic inflammation in obstructive lung disorders.

Pharmacology & therapeutics·2026
Same author

The Concise Guide to PHARMACOLOGY 2025/26: G protein-coupled receptors.

British journal of pharmacology·2025
Same author

Correction to: Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes.

World journal of urology·2025

Area of Science:

  • Urology
  • Pharmacology
  • Physiology

Background:

  • Urinary incontinence and storage symptoms are prevalent, with current treatments lacking efficacy and tolerability.
  • Rho kinase (ROCK) is crucial for bladder smooth muscle contraction.
  • ROCK signaling may be dysregulated in bladder pathologies.

Purpose of the Study:

  • To explore the therapeutic potential of Rho kinase (ROCK) inhibitors for bladder dysfunction.
  • To investigate the role of ROCK in pathological conditions affecting the bladder.

Main Methods:

  • In vitro studies using ROCK inhibitors (e.g., Y27632).
  • In vivo experiments utilizing animal models of bladder dysfunction.

Main Results:

Related Experiment Videos

  • ROCK inhibitors demonstrated potential in preclinical studies.
  • Experimental evidence suggests ROCK pathway modulation is beneficial for bladder function.

    • Conclusions:

    • ROCK inhibitors represent a promising therapeutic strategy for urinary storage symptoms and bladder dysfunction.
    • Targeting ROCK may offer improved treatment options for patients with limited efficacy and tolerability from current therapies.